Pharma & Biotech — 2026年10月12日 週次レポート
Pharma & Biotechのニュース＆アップデート — すべての記述に一次ソースのリンク付き。
重要な発見
エグゼクティブサマリー（5件）
- •The week's most consequential development was the convergence of legal, regulatory, and policy pressures reshaping the US and European pharmaceutical operating environment simultaneously: a Dutch court blocked Merck's subcutaneous Keytruda in eight European markets, PhRMA sued the Trump administration over Medicare drug pricing, and a 100% pharmaceutical tariff took effect — creating a multi-front policy crisis that disproportionately burdens smaller biotechs while large incumbents with MFN agre…
- •Regulatory agencies across three jurisdictions moved in parallel to institutionalize AI and clinical trial modernization: the UK government endorsed the NHS AI Commission's full recommendations and opened the MHRA AI Airlock Phase 3, the EMA permanently established its clinical trial application advice service from January 2027, and the FDA's new clinical trial modernization office within CDER continued its mandate — collectively signaling that AI-enabled regulatory pathways are transitioning fr…
- •China's role in global drug discovery deepened qualitatively this week: Roche's Defand Therapeutics deal marks a shift from licensing existing Chinese assets to co-discovering new ones, representing Roche's fourth China deal since August — a pace that signals Western pharma is embedding Chinese R&D capabilities into its core discovery engine rather than treating China as a supplementary licensing source.
- •The cell and gene therapy sector faces a bifurcated funding reality: Caribou Biosciences shut down despite FDA-aligned Phase 3 design and Nobel laureate co-founding credentials, while well-capitalized programs at J&J and others continue to advance — illustrating that scientific and regulatory credibility are necessary but insufficient conditions for survival in a capital-constrained environment where investor patience for long development timelines is limited.
- •The molecular glue therapy platform is emerging as the sector's next major drug discovery paradigm, with Roche's near-$1 billion Defand deal, Nature Biotechnology's scalable platform publication, and Revolution Medicines' Rasonque pancreatic cancer survival data collectively validating the modality — suggesting that companies with molecular glue capabilities will attract significant partnership and acquisition interest over the next 12-18 months.
今回の要点（14件）
- 1.A Dutch court ordered Merck to stop manufacturing and selling its subcutaneous Keytruda formulation in eight European countries, creating a material commercial risk for Merck's flagship oncology product [7].
- 2.Pfizer's TUKYSA regimen received FDA approval as a front-line maintenance treatment for HER2-positive metastatic breast cancer on 2026-10-07, extending its label into an earlier treatment setting [6].
- 3.The UK government backed in full the NHS doctors-led AI Commission's healthcare regulatory recommendations on 2026-10-06, and the MHRA's AI Airlock opened Phase 3 applications — making the UK the first major jurisdiction with a comprehensive government-endorsed AI healthcare regulatory framework [11].
- 4.The EMA announced its clinical trial applications advice pilot will become permanent from January 2027, providing ongoing pre-submission support for sponsors across the EU [3].
- 5.Caribou Biosciences, co-founded by Jennifer Doudna, shut down after failing to raise funding for a late-stage CAR-T lymphoma trial despite having finalized Phase 3 design with the FDA, illustrating a capital gap in cell and gene therapy [8a].
- 6.Roche struck its fourth China deal since August 2026, partnering with Defand Therapeutics to discover molecular glue medicines for cancer and immune diseases in a deal potentially worth close to $1 billion [8b].
- 7.PhRMA filed a lawsuit against the Trump administration asserting the GLOBE Medicare most-favored nation pilot exceeds statutory authority, escalating the legal confrontation over drug pricing policy [8c].
- 8.A 100% section 232 tariff on imported pharmaceuticals took effect at end of September 2026, with large drugmakers exempt via MFN agreements until 2029 but smaller biotechs facing immediate costs and limited guidance on exemptions [8d].
- 9.J&J presented two-year ICOTYDE Phase 3 data at Fall Clinical Dermatology showing nearly three-quarters of patients achieved clear or almost clear skin, building a durability case for the oral IL-23R peptide in psoriasis [10].
- 10.IFPMA Director General David Reddy published a major expert insight on 2026-10-09 arguing medicines and vaccines should be treated as strategic national assets, citing over 12,700 medicines in development and a USD 7 return for every USD 1 invested in NCD prevention [1a].
- 11.PMDA issued procurement notices for a next-generation safety signal detection system on 2026-10-06 and published an English translation of its biosimilar bioequivalence safety guidance on 2026-10-09, signaling Japan's modernization of pharmacovigilance infrastructure [4].
- 12.Vaxcyte claimed Phase 3 success for its pneumococcal vaccine, positioning it as a potential competitor to Pfizer and Merck in one of the most commercially significant vaccine markets [8].
- 13.Merck presented one-year BRUNELLO study results for remigromig in diabetic macular edema at AAO 2026 on 2026-10-10, continuing its ophthalmology pipeline build [2].
- 14.The FDA updated its biosimilar development Q&A guidance and postapproval manufacturing change guidance on 2026-10-09, alongside a Study Data Technical Conformance Guide update on 2026-10-08 [13].
市場動向
Pharmaceutical Innovation Reframed as Strategic National Economic Asset
IFPMA Director General David Reddy published a major expert insight on 2026-10-09 arguing that medicines and vaccines should be treated as strategic assets underpinning health security, economic resilience, and long-term prosperity — not merely healthcare products [1a]. The piece cited over 12,700 medicines currently in development, including over 9,600 targeting non-communicable diseases and more than 1,000 immunotherapies, and argued that every USD 1 invested in NCD prevention generates USD 7 …
Molecular Glue Therapies Emerge as Next Major Drug Discovery Platform
Roche struck a deal with Chinese startup Defand Therapeutics to discover molecular glue medicines for cancer and immune-driven diseases, with a source indicating the deal could be worth close to $1 billion including milestones, per STAT News on 2026-10-08 [8b]. Nature Biotechnology published a research briefing on a scalable platform to discover and characterize substrates of molecular glue degraders [9]. STAT News noted that development of molecular glue drugs has begun to accelerate, driven in…
US Pharmaceutical Tariff Regime Creates Asymmetric Burden on Smaller Biotechs
A 100% section 232 tariff on imported pharmaceuticals and their active ingredients took effect at the end of September 2026, per STAT News on 2026-10-08 [8d]. Large drugmakers that struck most-favored nation agreements are exempt from payment until early 2029, while smaller biotech firms lacking MFN deals face immediate tariff costs. STAT News reported that smaller companies say they are being left in the dark on how to obtain exemptions. This asymmetric burden — protecting large incumbents whil…
CAR-T and Cell Therapy Funding Remains Selective Despite Scientific Progress
Caribou Biosciences, co-founded by CRISPR Nobel laureate Jennifer Doudna, announced it is shutting down after failing to raise funding for a late-stage trial of its off-the-shelf CAR-T therapy for lymphoma, per STAT News on 2026-10-07 [8a]. The company had successfully finalized Phase 3 trial design with the FDA but could not secure financing. Endpoints News also reported that geographic atrophy biotech Aviceda shut down after a Phase 2 failure [7]. These closures, alongside the continued succes…
China Biotech Partnerships Evolve From Licensing to Co-Discovery
Roche's deal with Defand Therapeutics marks a qualitative shift in Western pharma's China strategy: rather than licensing existing clinical-stage assets, Roche is enlisting a Chinese startup to discover entirely new medicines, per STAT News on 2026-10-08 [8b]. STAT News reported this is Roche's fourth China deal since August 2026 [7]. STAT News's earlier reporting on the Jefferies Shanghai conference described Chinese biotech executives boasting about running trials faster and cheaper than Weste…
競合動向
Merck Faces European Legal Setback on Subcutaneous Keytruda Formulation
A Dutch court ordered Merck to stop manufacturing and selling its injectable formulation of Keytruda in eight European countries, per Endpoints News on 2026-10-08 [7]. STAT News also reported on this setback on 2026-10-07 [8]. Separately, Merck presented one-year results from the pivotal Phase 2b/3 BRUNELLO study evaluating remigromig in adults with diabetic macular edema at AAO 2026 on 2026-10-10 [2] (company announcement — may reflect promotional framing). The European legal setback on Keytrud…
Pfizer Secures FDA Approval for TUKYSA as Front-Line HER2+ Breast Cancer Maintenance
Pfizer's TUKYSA regimen received FDA approval as a front-line maintenance treatment for HER2-positive metastatic breast cancer on 2026-10-07, per Pfizer's press release listing [6] (company announcement — may reflect promotional framing). This approval extends TUKYSA's label into an earlier treatment setting, potentially expanding the addressable patient population and reinforcing Pfizer's position in HER2-targeted oncology. Combined with the prior period's positive Phase 2 data for tilrekimig i…
Johnson & Johnson Builds Long-Term Durability Case for ICOTYDE in Psoriasis
J&J presented new ICOTYDE (icotrokinra) Phase 3 data at Fall Clinical Dermatology on 2026-10-09, showing that nearly three-quarters of adults and adolescents achieved clear or almost clear skin at two years with a continued favorable safety profile [10] (company announcement — may reflect promotional framing). This follows the 2026-10-02 announcement of ICOTYDE data in difficult-to-treat plaque psoriasis showing 60% scalp clearance and 89% genital clearance at Week 112. The accumulation of two-y…
Roche Deepens China R&D Engagement With Fourth Deal Since August
Roche's partnership with Defand Therapeutics for molecular glue discovery, reported by STAT News on 2026-10-08, is described as Roche's fourth China deal since August 2026 [7]. Roche also enlisted Alector in a Parkinson's deal paying $100 million upfront, per Endpoints News [7]. This pattern of rapid, multi-front deal-making — spanning China co-discovery, neurology licensing, and molecular glue platforms — signals that Roche is aggressively rebuilding its pipeline through external partnerships a…
Vaxcyte Claims Phase 3 Success Against Pfizer and Merck in Pneumococcal Vaccine Market
Vaxcyte claimed success in a Phase 3 study for its pneumococcal vaccine, positioning it as a potential competitor to Pfizer and Merck in the lucrative pneumococcal vaccine market, per STAT News on 2026-10-05 [8]. Endpoints News also reported the stock surged following the Phase 3 success [7]. This development introduces a new competitive dynamic into one of the most commercially significant vaccine markets, where Pfizer's Prevnar franchise and Merck's Vaxneuvance have dominated. A successful Vax…
制度・規制動向
UK Government Backs AI Commission Recommendations and MHRA AI Airlock Advances
On 2026-10-06, the UK government backed in full the recommendations of the NHS doctors-led National Commission on the Regulation of AI in Healthcare, while the MHRA's AI Airlock opened its next phase (Phase 3 applications) [11]. The MHRA also published guidance on good machine learning practice for medical device development on 2026-10-05 [11]. This represents a significant policy milestone: the UK is now the first major jurisdiction to formally adopt a comprehensive government-backed AI regulat…
EMA Permanently Establishes Clinical Trial Application Advice Pilot From January 2027
The EMA announced on 2026-10-08 that its clinical trial applications advice pilot will become permanent, with technical and regulatory support for preparing clinical trial applications continuing from January 2027 [3]. This institutionalization of pre-submission advice for clinical trial applications reduces uncertainty for sponsors and signals the EMA's commitment to proactive regulatory engagement — a direct competitive response to the UK's 14-day Phase 1 assessment programme and the US FDA's …
PMDA Launches Next-Generation Signal Detection System Procurement and Advances Biosimilar Standards
Japan's PMDA issued two government procurement notices on 2026-10-06 for a next-generation safety signal detection system, covering both the signal detection product introduction and the associated safety support system modification [4]. On 2026-10-09, PMDA published the 37th Generic Drug and Biosimilar Quality Information Review Meeting and updated its drug risk management plan documentation examples [4]. PMDA also published an English translation of its Early Consideration on bioequivalence te…
PhRMA Sues Trump Administration Over GLOBE Medicare Drug Pricing Program
PhRMA filed a lawsuit against the Trump administration asserting that the GLOBE most-favored nation pilot in Medicare Part B exceeds Medicare's statutory authority, per STAT News on 2026-10-08 [8c]. Endpoints News also reported on the lawsuit [7]. PhRMA argues that while voluntary MFN agreements are acceptable, the mandatory GLOBE program is not. The lawsuit, combined with the pharmaceutical tariff regime, represents an escalating legal and policy confrontation between the US pharma industry and…
FDA Updates Biosimilar Development Guidance and Study Data Technical Standards
The FDA published updated questions and answers on biosimilar development and the BPCI Act on 2026-10-09, along with updated guidance on postapproval manufacturing changes to biosimilar and interchangeable biosimilar products [13]. The FDA also updated its Study Data Technical Conformance Guide on 2026-10-08 [13]. These simultaneous updates to biosimilar development and manufacturing change guidance signal the FDA is actively refining the regulatory framework for the growing biosimilar market, w…
ソース活動
先週からの変化
Dutch Court Blocks Merck's Subcutaneous Keytruda in Eight European Countries
A Dutch court ordered Merck to stop manufacturing and selling its injectable subcutaneous formulation of Keytruda in eight European countries, per Endpoints News and STAT News reporting on 2026-10-07 and 2026-10-08 [7]. This is a material commercial setback for Merck's flagship oncology franchise, as the subcutaneous formulation was positioned as a key patient convenience differentiator. The ruling creates uncertainty about the European commercial trajectory of Merck's most important product.
UK Government Backs AI Healthcare Commission Recommendations; MHRA AI Airlock Phase 3 Opens
On 2026-10-06, the UK government backed in full the NHS doctors-led National Commission's AI healthcare regulatory recommendations, and the MHRA's AI Airlock opened Phase 3 applications [11]. This makes the UK the first major jurisdiction with a comprehensive government-endorsed AI healthcare regulatory framework, creating a structural advantage for AI-enabled medical product developers.
EMA Clinical Trial Application Advice Pilot Made Permanent From January 2027
The EMA announced on 2026-10-08 that its clinical trial applications advice pilot will become a permanent service from January 2027, providing ongoing technical and regulatory support for sponsors preparing clinical trial applications [3]. This institutionalization gives sponsors a concrete planning horizon and reduces pre-submission uncertainty across the EU.
Pfizer's TUKYSA Receives FDA Approval as Front-Line HER2+ Metastatic Breast Cancer Maintenance
Pfizer's TUKYSA regimen received FDA approval as a front-line maintenance treatment for HER2-positive metastatic breast cancer on 2026-10-07 [6] (company announcement — may reflect promotional framing). This label expansion into an earlier treatment setting extends TUKYSA's addressable patient population and strengthens Pfizer's HER2-targeted oncology franchise.
Caribou Biosciences Shuts Down; CAR-T Funding Gap Widens
Caribou Biosciences, co-founded by CRISPR Nobel laureate Jennifer Doudna, announced it is shutting down after failing to raise funding for a late-stage CAR-T lymphoma trial despite having finalized Phase 3 design with the FDA, per STAT News on 2026-10-07 [8a]. The closure illustrates that scientific credibility and regulatory alignment are insufficient without investor capital, highlighting a funding gap in the cell and gene therapy sector.
ウォッチリスト — 今後の締切
EMA clinical trial applications advice pilot becomes permanent service — effective January 2027
ソース: EMA NewsFDA approval decision expected for BridgeBio's infigratinib (oral treatment for achondroplasia in children) — priority review granted
ソース: STAT News示唆・見るべき論点（9件）
- 1.The Dutch court ruling blocking Merck's subcutaneous Keytruda in eight European countries exposes a structural vulnerability in Merck's European oncology strategy: its most important product's next-generation formulation is now legally constrained in a major market. Companies developing subcutaneous reformulations of existing biologics should audit their European IP and regulatory positions before commercial launch to avoid analogous disruptions.
- 2.The UK's full government endorsement of the AI Commission's healthcare recommendations, combined with the MHRA AI Airlock Phase 3 opening, creates the world's most advanced regulatory sandbox for AI medical products [11]. Companies developing AI-enabled diagnostics, drug discovery tools, or clinical decision support should evaluate the UK as a primary regulatory entry point, as first-mover advantage in the AI Airlock could translate into faster global approvals.
- 3.The EMA's permanent clinical trial application advice service from January 2027 [3] creates a concrete planning opportunity: sponsors with EU clinical trial applications planned for 2027 should engage with EMA's pre-submission advice process now to shape trial designs before submission, reducing the risk of protocol amendments that delay timelines.
- 4.Caribou's shutdown despite FDA-aligned Phase 3 design [8a] is a warning signal for the broader off-the-shelf CAR-T field: regulatory alignment is not a sufficient proxy for investor confidence. Companies in this space should prioritize demonstrating commercial differentiation and cost-of-goods advantages over autologous CAR-T in investor communications, not just clinical efficacy.
- 5.Roche's shift from licensing Chinese clinical-stage assets to co-discovering new ones with Defand Therapeutics [8b] represents a strategic deepening that carries both opportunity and risk: co-discovery partnerships require more intensive IP governance than licensing deals, and the molecular glue modality's novelty means that IP boundaries between partners are less well-established than in small molecule or antibody licensing.
- 6.The pharmaceutical tariff's asymmetric impact — exempting large MFN-agreement holders until 2029 while exposing smaller biotechs to immediate costs [8d] — is likely to accelerate M&A activity as smaller companies with imported API dependencies seek the shelter of larger acquirers' MFN agreements. Biotech companies with significant imported active ingredient exposure should model acquisition scenarios as a near-term strategic option.
- 7.IFPMA's framing of pharmaceutical innovation as generating USD 7 in return for every USD 1 invested in NCD prevention [1a] is a deliberate counter-narrative to drug pricing pressure: by quantifying the economic return on pharmaceutical investment, IFPMA is building the evidentiary case for governments to resist price controls. Companies facing pricing negotiations in OECD markets should incorporate this economic return framing into their value dossiers.
- 8.Vaxcyte's Phase 3 pneumococcal vaccine success [8] introduces a new competitive dynamic into a market where Pfizer and Merck have operated as a duopoly. Both incumbents should model market share scenarios that include a third entrant, as pneumococcal vaccine pricing has historically been supported by limited competition — a dynamic that a successful Vaxcyte approval would fundamentally alter.
- 9.The FDA's simultaneous updates to biosimilar development Q&A, postapproval manufacturing change guidance, and study data technical standards on 2026-10-08 and 2026-10-09 [13] signal an active regulatory refinement cycle for biosimilars. Companies with pending biosimilar applications or interchangeable designation requests should review these updated guidances immediately to assess whether their submissions require supplemental data or procedural adjustments.
信頼度サマリー
今週引用したソース 13 件あなたが選んだ 15 件の監視URLから検出（1つのURLから複数記事が出ることがあります）。
各ソースは信頼度レベルに応じて重み付けされています。単独ソースの主張は AI 合成時に未検証としてフラグ付けされます。
参照ソース一覧
IFPMA expert insight by Director General David Reddy on pharmaceutical innovation as a strategic investment in health and growth, published 2026-10-09, citing over 12,700 medicines in development and USD 7 return per USD 1 invested in NCD prevention.
Merck press releases covering one-year BRUNELLO study results for remigromig in diabetic macular edema presented at AAO 2026 on 2026-10-10, and Q3 2026 earnings call announcement.
EMA news covering the permanent establishment of the clinical trial applications advice pilot from January 2027 (announced 2026-10-08), EMA recommendation for Bovilis Lumpyvax veterinary vaccine, and CVMP October meeting highlights.
PMDA publications covering next-generation signal detection system procurement notices (2026-10-06), 37th Generic Drug and Biosimilar Quality Information Review Meeting (2026-10-09), updated drug risk management plan documentation (2026-10-09), and English translation of bioequivalence test safety Early Consideration (2026-10-09).
EFPIA blog article on cancer medicine access disparities across Europe (2026-10-08) and upcoming events including the Cardiovascular Health Plans event on 2026-10-15 and TOPRA Symposium on 2026-10-19.
Pfizer press releases covering TUKYSA FDA approval as front-line maintenance treatment for HER2-positive metastatic breast cancer (2026-10-07) and Q4 2026 dividend declaration (2026-10-06).
Endpoints News reporting on Merck's Dutch court Keytruda setback, Roche's fourth China deal with Defand Therapeutics, Caribou Biosciences shutdown, Vaxcyte Phase 3 pneumococcal vaccine success, Shionogi's $2B IntraBio acquisition, pharmaceutical tariff impacts on smaller biotechs, and PhRMA lawsuit against Trump administration.
STAT News reporting on Roche-Defand molecular glue deal, Caribou Biosciences shutdown, pharmaceutical tariff impacts on smaller biotechs, PhRMA GLOBE lawsuit, Vaxcyte Phase 3 success, China biotech Jefferies conference, HHS SURPASS AI trial program, and NIH funding uncertainty.
Nature Biotechnology research articles on highly multiplexed mammalian metabolic engineering with shotgun approach (2026-10-06), AI-guided optimization for thermostable mRNA vaccines, lipid nanoparticles for large RNA cargo, and molecular glue degrader substrate discovery platform.
J&J press releases covering new ICOTYDE two-year Phase 3 data in adults and adolescents with plaque psoriasis presented at Fall Clinical Dermatology (2026-10-09), showing nearly three-quarters achieving clear or almost clear skin at two years.
MHRA publications covering UK government endorsement of NHS AI Commission recommendations and MHRA AI Airlock Phase 3 opening (2026-10-06), MHRA approval of catumaxomab for malignant ascites (2026-10-07), good machine learning practice guidance for medical devices (2026-10-05), and digital mental health technology framework (2026-10-08 and 2026-10-09).
DIA Global articles on comparing clinical development lifecycles of Chinese local companies versus MNCs, eCTD v4.0 first submission in Japan, and the DIA-MHRA Global Summit.
FDA drug news covering updated biosimilar development Q&A and BPCI Act guidance (2026-10-09), postapproval manufacturing changes to biosimilar products guidance (2026-10-09), and Study Data Technical Conformance Guide update (2026-10-08).
Pharma & Biotechを毎週、自動で監視
このレポートは一次ソースのみから生成されています。テーマとソースを選べば、引用付きレポートが毎週届きます。7日間無料トライアル・$33/月から。
無料トライアルを始める